作為一個(gè)始終以創(chuàng)新為先的產(chǎn)業(yè)，生物技術(shù)吸引了許多年輕的創(chuàng)業(yè)者，他們的想法可能會(huì)改變世界。歐洲知名生命科學(xué)網(wǎng)站（Labiotech.eu）近日列出了歐洲新一代生物技術(shù)公司背后的一些最具開(kāi)創(chuàng)力的領(lǐng)導(dǎo)者名單。

1、Thomas Ybert

法國(guó)生物技術(shù)公司DNA Script的聯(lián)合創(chuàng)始人兼CEO

Thomas于2014年創(chuàng)建了DNA Script，當(dāng)時(shí)他只有30歲。在完成生物技術(shù)博士學(xué)位后，Thomas在賽諾菲工作，之后為Amyris和Total開(kāi)發(fā)生物燃料。在這個(gè)行業(yè)的從業(yè)經(jīng)驗(yàn)中，Thomas注意到編寫(xiě)DNA的技術(shù)落后于讀取DNA的技術(shù)。Thomas與另外兩位杰出的年輕企業(yè)家Sylvain Gariel（COO）和Xavier Godron（CTO）共同創(chuàng)建了DNA Script。他們一起決定開(kāi)發(fā)一種新的生物方法，這種方法可以比目前的化學(xué)技術(shù)更快、更準(zhǔn)確、更經(jīng)濟(jì)地合成DNA。到目前為止，該公司表現(xiàn)良好，在2017年的A輪融資中籌集到了1100萬(wàn)美元。

創(chuàng)新融資的新方法

Kurma Partners成立于2009年7月，是醫(yī)療保健和生物技術(shù)創(chuàng)新融資的歐洲主要參與者，從種子前到成長(zhǎng)資本，特別是通過(guò)Kurma Biofund I，II和Kurma Diagnostics，以及通過(guò)與著名的戰(zhàn)略合作伙伴關(guān)系歐洲研究和醫(yī)療機(jī)構(gòu)。

Kurma Partners在整個(gè)價(jià)值鏈中運(yùn)營(yíng)，并開(kāi)展以下活動(dòng)：

Kurma Biofund I的基金管理（規(guī)模為5100萬(wàn)歐元）Kurma Biofund I是一家專注于生命科學(xué)和醫(yī)療保健的投資基金。它致力于建立創(chuàng)新融資的新經(jīng)濟(jì)模式：基于與法國(guó)和歐洲最著名的生物技術(shù)和醫(yī)學(xué)研究中心的戰(zhàn)略合作伙伴關(guān)系的模式。Kurma Biofund I對(duì)早期項(xiàng)目特別感興趣，即使是那些處于技術(shù)前沿的項(xiàng)目，旨在將它們轉(zhuǎn)變?yōu)榭尚械膭?chuàng)業(yè)項(xiàng)目，并在三到五年內(nèi)實(shí)現(xiàn)它們。

Kurma Biofund II的基金管理，目標(biāo)規(guī)模為5500萬(wàn)歐元，KBII是一個(gè)風(fēng)險(xiǎn)基金，按照與Kurma Biofund I相同的方法建立，重點(diǎn)關(guān)注罕見(jiàn)疾�。ㄖ辽僬蓟�金的50％）。該基金的四個(gè)主要LP是GSK，BPI France，NEA（New Entreprise Associates）和Idinvest Partners。

Kurma Diagnostics的資金管理，KDx，2015年5月首次收到33,300萬(wàn)歐元，是一家專門(mén)致力于診斷解決方案（IVD，設(shè)備和數(shù)字健康）項(xiàng)目和公司的加速基金。KDx建立在KBI期間在診斷領(lǐng)域進(jìn)行的成功投資的基礎(chǔ)上。該基金受益于與診斷領(lǐng)域的主要?dú)W洲機(jī)構(gòu)的多個(gè)合作伙伴關(guān)系。

根據(jù)咨詢要求管理Idinvest Partners的Biotech投資組合，前身為AGF Private Equity（“Idinvest Biotech”）。該投資組合包括13家公司，其中3家已退出，10家已上市�？偼顿Y規(guī)模約為1億歐元。Kurma Partners繼續(xù)為生命科學(xué)投資中的IdInvest提供建議，與Kurma基金共同投資。與kurma基金共同投資策略。

巴黎Saclay種子基金，Kurma管理該基金的醫(yī)療投資，主要是診斷和數(shù)字健康。

戰(zhàn)略

能夠在整個(gè)價(jià)值鏈上投資從早期公司到上市公司更成熟的公司

Kurma Partners在生命科學(xué)領(lǐng)域（公司組建，種子基金）的“早期階段”投資中開(kāi)發(fā)了一套獨(dú)特的技能。該分部約占Kurma投資活動(dòng)的40％。

生命科學(xué)行業(yè)更為傳統(tǒng)的創(chuàng)業(yè)階段，占我們投資的50％。最終的10％由增長(zhǎng)資本（增長(zhǎng)

上市公司）占據(jù)。我們?cè)诠�司所有前面提到的階段進(jìn)行投資的能力是一項(xiàng)獨(dú)特的資產(chǎn)，可以增加我們的投資成功。

定義

資本投資是改善健康和環(huán)境的手段

Kurma Partners的團(tuán)隊(duì)相信資本投資的優(yōu)點(diǎn)，可以加快研究成果，將其轉(zhuǎn)化為可行的公司項(xiàng)目，并通過(guò)開(kāi)發(fā)新藥，診斷產(chǎn)品和設(shè)備為改善我們的生活做出貢獻(xiàn)。我們的業(yè)務(wù)是將健全和可持續(xù)的項(xiàng)目轉(zhuǎn)讓給工業(yè)合作伙伴。投資的財(cái)務(wù)業(yè)績(jī)代表著一種價(jià)值創(chuàng)造鏈，其基礎(chǔ)是企業(yè)家的勇氣以及工業(yè)，經(jīng)濟(jì)，人類，社會(huì)和社會(huì)發(fā)展之間的緊密聯(lián)系。

Kurma Partners的行動(dòng)基于某些價(jià)值觀和原則：

引入所有參與風(fēng)險(xiǎn)資本投資的人的利益，無(wú)論是保證投資者最有效地利用其資本還是使其他合作伙伴能夠獲得其工作成果。

對(duì)研究和管理團(tuán)隊(duì)做出明確和透明的承諾。

就共同目標(biāo)以及建立和實(shí)施基于信心的投資者 - 企業(yè)家關(guān)系的所有運(yùn)營(yíng)方式達(dá)成一致。

相信創(chuàng)造企業(yè)的好處，回歸企業(yè)的先驅(qū)精神，并使其發(fā)揮作用。

尊重我們受托的人力和財(cái)力資源。

探索新的領(lǐng)域，無(wú)論是在融資項(xiàng)目，與研究中心的關(guān)系，投資策略還是我們項(xiàng)目的財(cái)務(wù)模型方面。

Kurma Biofund I

KURMA BIOFUND I：致力于生命科學(xué)的投資基金

Kurma Biofund I，規(guī)模為5100萬(wàn)歐元，于2009年11月推出。它由11家活躍的生命科學(xué)公司組成�；�金與研究機(jī)構(gòu)合作創(chuàng)建了該投資組合中的五家公司。

我們的投資原則和方法

通過(guò)Kurma Biofund I，Kurma Partners的投資方法強(qiáng)調(diào)了一種選擇性的風(fēng)險(xiǎn)方法，而不是投資領(lǐng)域內(nèi)的極端多樣化。對(duì)于每項(xiàng)投資，Kurma Partners專注于有限數(shù)量的科學(xué)項(xiàng)目

應(yīng)用。

技術(shù)轉(zhuǎn)讓（TT）：

首次投資在150,000至500,000歐元之間，以開(kāi)發(fā)和測(cè)試科學(xué)假設(shè)，并證明研究所涉概念的適用性。總和可以快速獲得，Kurma Partners可以選擇研究結(jié)果。

根據(jù)項(xiàng)目開(kāi)發(fā)的速度，Kurma在項(xiàng)目期間（從三年到五年，最多七年）分多次提供多達(dá)500萬(wàn)歐元的資金。

Kurma Partners的TT投資策略基于以下原則：

傾向于將自己與研究中心和研究人員創(chuàng)建的公司的資本相關(guān)聯(lián)，而不是與版稅協(xié)議相關(guān)聯(lián)。這帶來(lái)了更快的收益的可能性。因此，研究中心和研究人員保留了大量的少數(shù)股權(quán)，基金是大股東。

成立董事會(huì)，由創(chuàng)建該項(xiàng)目的研究人員（如果他們?cè)敢猓┖驮谏�物醫(yī)學(xué)發(fā)現(xiàn)領(lǐng)域具有相關(guān)經(jīng)驗(yàn)的專業(yè)人士組成。日常管理由具有生物醫(yī)學(xué)行業(yè)背景的經(jīng)驗(yàn)豐富的管理人員執(zhí)行，他們能夠?yàn)楦毖芯咳藛T提供他們經(jīng)驗(yàn)的好處。

研究人員可以自由地繼續(xù)他們的學(xué)術(shù)研究活動(dòng)，同時(shí)與已經(jīng)成立的公司保持聯(lián)系，但需要任何委員會(huì)同意處理利益沖突。

冒險(xiǎn)

這是每個(gè)項(xiàng)目投資100萬(wàn)至500萬(wàn)歐元，一次性付款

多次付款。這些投資在日常運(yùn)作方面更為經(jīng)典，并受益于至少一個(gè)基金合作伙伴的承諾。

資本發(fā)展/上市公司

這涉及每筆交易高達(dá)500萬(wàn)歐元的投資，通常一次性全部發(fā)放�；�于與該部門(mén)經(jīng)營(yíng)的金融組織網(wǎng)絡(luò)的聯(lián)系，這種投資是有限的和機(jī)會(huì)主義的。重點(diǎn)是低估公司的生物醫(yī)藥產(chǎn)品的高附加值機(jī)會(huì)。

contact**[ta]**cript.com

29 rue du Faubourg Saint Jacques

75014，Pari***

FRANCE 法國(guó)

Kurma合作伙伴

24號(hào)，皇家街/ 5E ETAGE

75008巴黎 法國(guó)

電話：+33（0）1 84 86 0***

contact**[ta]**apartners.com

德國(guó)

Maximilianstraße29

80539慕尼黑 德國(guó)

2、Laura Soucek

西班牙生物技術(shù)公司Peptomyc的聯(lián)合創(chuàng)始人兼CEO

作為一名成功的癌癥研究者，Laura于2014年創(chuàng)立了Peptomyc，目的是將自己的研究轉(zhuǎn)化為新一代的癌癥治療方法。她在巴塞羅那瓦爾赫伯倫腫瘤研究所結(jié)識(shí)了共同創(chuàng)始人兼CSO Marie-Eve Beaulieu。Peptomyc公司正在開(kāi)發(fā)一種能穿透癌細(xì)胞并殺死癌細(xì)胞的肽類藥物。最重要的是，這種療法已顯示出治療癌癥的希望，而且不存在通常與癌癥治療（如化療）相關(guān)的嚴(yán)重副作用。2018年7月，該公司從西班牙風(fēng)險(xiǎn)投資公司Alta Life Sciences籌集了420萬(wàn)歐元。

Dr. Laura Soucek

laura-soucek

Co-Founder and Chief Executive Officer (CEO) of Peptomyc S.L.

Principal Investigator of the Mouse Models of Cancer Therapies Group at the Vall d´Hebron Institute of Oncology (VHIO) and ICREA Professor. Dr. Soucek is a leading figure in the Myc field and has pioneered studies on MYC inhibition since designing Omomyc when she was still an undergraduate student. Dr. Laura Soucek has published in top scientific journals including Nature, Nature Medicine, Genes & Development, and Nature Communications as First and Senior author. Since early 2011, she heads the Mouse Models of Cancer Therapies Group at the Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Her research at VHIO has already been recognized through several national research awards and grants (FERO fellowship, grants from the Miguel Servet Program, FIS and AGAUR), and prestigious international grants such as an ERC Consolidator grant, two ERC Proof of Concept grants and an AICR (now Worldwide Cancer Research) grant. Laura is also co-inventor of three patent applications including the ones at the basis of this project. In December 2014, she co-founded Peptomyc S.L. As CEO of the company, she is directing the scientific and strategic aspects of the project, overseeing its overall implementation, progress, and success.

Relevant publications：

Dang CV, Reddy EP, Shokat KM, Soucek L. Nat Rev Cancer. 2017 Aug;17(8)：502***

Whitfield JR, Beaulieu ME and Soucek L (2017) Front. Cell Dev. Biol. 5：10

Beaulieu ME, Jauset T, Massó-Vallés DM, Soucek L, and Whitfield JR (2017) Cancer Genetics and Genomics for Personalized Medicine. Edited by Il-Jin Kim

Annibali, D., Whitfield, J.R., Favuzzi, E., Jauset, T., Serrano, E., Cuartas, I., Redondo-Campos, S., Folch, G., Gonzalez-Junca, A., Sodir, N.M., et al. (2014). Nature Communications 5, 4***

Soucek, L., Whitfield, J.R., Sodir, N.M., Masso-Valles, D., Serrano, E., Karnezis, A.N., Swigart, L.B., and Evan, G.I. (2013). Genes & Development 27, 504-***

Sodir, N.M., Swigart, L.B., Karnezis, A.N., Hanahan, D., Evan, G.I., and Soucek, L. (2011). Genes & Development 25, 907-***

Savino, M., Annibali, D., Carucci, N., Favuzzi, E., Cole, M.D., Evan, G.I., Soucek, L., and Nasi, S. (2011). PloS One 6, e22***

Soucek, L., Whitfield, J., Martins, C.P., Finch, A.J., Murphy, D.J., Sodir, N.M., Karnezis, A.N., Swigart, L.B., Nasi, S., and Evan, G.I. (2008). Nature 455, 679-***

Soucek, L., Nasi, S., and Evan, G.I. (2004). Cell Death and Differentiation 11, 1038-1***

Soucek, L., Jucker, R., Panacchia, L., Ricordy, R., Tato, F., and Nasi, S. (2002). Cancer Research 62, 3507-3***

Soucek, L., Helmer-Citterich, M., Sacco, A., Jucker, R., Cesareni, G., and Nasi, S. (1998). Oncogene 17, 2463-2***

Dr. Marie-Eve Beaulieu

marie-eve-beaulieu

Co-Founder & Chief Scientific Officer (CSO) of Peptomyc S.L.

Senior Postdoctoral Fellow in Dr. Soucek’s Mouse Models of Cancer Therapies Group at the Vall d´Hebron Institute of Oncology (VHIO).

Dr. Beaulieu has extensive experience in biochemistry and structural biology of b-HLH-LZ transcription factors (such as Omomyc) and peptide design. In parallel to her academic career, she worked with the pharmaceutical industry and studied peptide formulations using various biophysical methods such as Nuclear Magnetic Resonance, Circular Dichroism and Fluorescence spectroscopies. Marie-Eve graduated in November 2011 (PhD in Pharmacology, Université de Sherbrooke, Canada), and was awarded several competitive fellowships (CREFSIP scholarship grant (PhD project), MITACS Accelerated postdoctoral fellowship (postdoc project at Theratechnologies Inc., Montreal, Canada) and a FRSQ postdoctoral award from the Quebec government (current postdoc project)). She already co-authored 13 peer-reviewed publications and

2 book chapters. In 2012, she joined Dr. Soucek’s laboratory as a postdoctoral fellow and unveiled the cell-penetrating properties of the purified Omomyc peptide. She is co-inventor of the patent application protecting the use of Omomyc in medicine and co-founder of Peptomyc S.L. with the aim of translating years of academic research into a practical value for society. As CSO of Peptomyc, Marie-Eve will coordinate the activities performed by the CROs and perform and supervise the activities related to the Omomyc peptide development (preclinical validation in vitro and in vivo) within the lab.

Genesis Biomed

GENESIS Biomed is a start-up formed by entrepreneurs and with vocation of service to entrepreneurs and research centers.They have been involved as strategic consultants since the very beginning, helping the company in strategy, business development, regulatory affairs and fundraising.

Vantum Corporate

Vantum Corporate (CFO).

Peptomyc Research Team

Dr. Francisco Castillo

Dr. Castillo is the newest addition to the research team and has extensive experience at the early stages of drug discovery. As a PhD student, he designed the best-in-class cell penetrating peptides against Ebola and Marburg filoviridae. During his industrial placement, he contributed to the discovery of natural products and small molecules against FoxO3a aberrant nuclear translocation viaphenotypical high-content screening. As a Cancer Research UK postdoctoral fellow he implemented a FRET-based screening platform, which led to the identification of novel fragments specifically targeting cRaf interaction with kRAS-G12D. He has co-authored 6 peer-reviewed publications and 2 book chapters as first author. Francisco is now characterizing the biopharmaceutical stability of Omomyc for further formulation development.

Dr. Laia Foradada

Dr. Foradada joined Peptomyc in 2016 as an expert in in vivostudies and pathology. She graduated in Veterinary Medicine (UAB; 2006) and then moved to the Histology and Pathology Department where she obtained a PhD in Animal Medicine and Health (CBATEG, UAB; 2013) and extensive knowledge in anatomy, pathology and animal surgery. Afterwards she worked in the Functional Validation and Preclinical Research group (CIBBIM-Nanomedicine, VHIR) where she developed her expertise in mouse models, functional and preclinical validation of new compounds and skills in molecular imaging techniques. Laia is co-author of 9 peer-reviewed publications.

Dr. Silvia Casacuberta

Dr. Casacuberta is an expert immuno-oncology scientist who joined Peptomyc in 2016 as a postdoctoral researcher. She has a master in Biomedicine (Universitat de Barcelona; 2011) and a PhD in Immunology (Universitat Autònoma de Barcelona; 2016). During her PhD she designed a method to induce immune tolerance in a model of multiple sclerosis and has already co-authored 8 peer-reviewed publications, 2 of which as a first author. In order to elucidate the role of Myc in orchestrating immune evasion, Silvia is applying her extensive knowledge of the immune system to investigate how Myc inhibition modulates the anti-tumor immune response in different cancer models.

Dr. Toni Jauset

Dr. Jauset has wide experience in the preclinical validation of cancer therapies. He graduated in Biotechnology (Universitat de Lleida, 2010) and obtained a Master in Molecular Medicine (Cranfield University, 2011), before completing his PhD under Dr. Laura Soucek’s supervision. During his thesis, Toni investigated the mode of action of the Omomyc transgene and helped characterize the effects of the Omomyc mini-protein in NSCLC. He also collaborated with various laboratories to develop Omomyc-based nanoparticles and with pharmaceutical companies to test their drugs in mouse models. He is co-author of 5 peer-reviewed publications and 2 patents. After working in Dr. Soucek’s laboratory for several years, Toni joined Peptomyc’s team in 2017 to continue the preclinical development of Omomyc-based pharmacological approaches.

Dr. Daniel Massó-Vallés

Dr. Massó-Vallés graduated in Biology at the Autonomous University of Barcelona (2009), and obtained a Master degree in Advanced Genetics from the same university (2010). He then received a PhD in Biochemistry, Molecular Biology and Biomedicine in Dr. Laura Soucek’s laboratory (2017), where he studied the role of Myc in metastatic breast cancer and the repurposing of ibrutinib for the treatment of pancreatic cancer. He recently joined Peptomyc after being awarded a ‘Torres Quevedo’ fellowship to validate a new generation of cell penetrating peptides targeting Myc for breast cancer treatment. Daniel is co-author of 6 peer-reviewed publications (2 as first author), a book chapter and a patent application.

Scientific Advisory Board (SAB)

Peptomyc S.L. benefits from the expertise of a strong Scientific Advisory Board (SAB) comprising the following internationally renowned thought leaders in oncology：

josep-tabernero

Head of the Medical Oncology Department of the Vall d’Hebron University Hospital; Director of the Vall d’Hebron Institute of Oncology, Barcelona, Spain.

Josep Tabernero holds MD and PhD degrees from the Universitat Autònoma de Barcelona, Spain. He is currently Head of the Medical Oncology Department at the Vall d’Hebron Barcelona Hospital Campus, Director of the Vall d’Hebron Institute of Oncology (VHIO), and leads the Research Innovation of Catalonian Cancer Centers Network.

He also directs VHIO´s Gastrointestinal and Endocrine Tumors Group, the Research Unit for Molecular Therapy of Cancer (UITM) - “l(fā)a Caixa”, and is Principal Investigator of several Phase I pharmacodynamic studies and translational projects with molecular targeted therapies, with particular emphasis on EGFR-family inhibitors and IGFR-PI3K-Akt-mTOR pathway inhibitors, as well as phase II and III studies with novel chemotherapeutics.

Based on the idea that each tumor has an independent genetic identity, his group aims at potentiating molecular therapies targeting specific oncoproteins and accelerating more effective personalized cancer medicines for patients displaying genetic lesions or pathway disregulation. One of his team´s main objectives is to establish novel predictive markers of response to anti-cancer therapies and identify markers of primary resistance (de novo) and secondary treatment.

At preclinical level, in collaboration with VHIO´s cancer researchers and physician-scientists, he develops new xenograft models with explant tumors from patients (“xenopatients”) in mice in order to mimic the patient’s disease and study tumor development in optimal research models. He also leads research into the study of circulating biomarkers (detection and genotyping of circulating free DNA), and is dedicated to advancing the immuno-oncology field through a large portfolio of trials with some of the most promising targets in immune checkpoints and cytokines. By paring immune therapeutics with oncogenomics, his team seeks to render anti-cancer therapies more precise.

Dr. Tabernero serves on the Editorial Boards of various top tier journals includingAnnals of Oncology, ESMO Open, Cancer Discovery andClinical Cancer Research. He has (co) authored approximately 350 peer-reviewed pape***

He is currently President (2018 - 2019) of the European Society for Medical Oncology´s (ESMO), and also serves as member of its Executive Board. He is also member of the American Association for Cancer Research (AACR), the American Society of Clinical Oncology (ASCO), and has been appointed as member of several Educational and Scientific Committees of ESMO, ECCO, ASCO, AACR, AACR/NCI/EORTC, ASCO Gastrointestinal, and WCGIC meetings.

Roger-Stupp

Chief of Neuro-oncology in the Department of Neurology, Northwestern Medicine, Feinberg School of Medicine

Professor of Neurological Surgery, Neurology, and Oncology, Northwestern University Feinberg School of Medicine

Co-Director, Northwestern Brain Tumor Institute

Associate Director for Strategic Initiatives, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago Illinois

Roger Stupp trained in Internal Medicine, Oncology/Hematology in Switzerland and at the University of Chicago. He worked over 17 years as a physician and researcher at the University of Lausanne, before being appointed in 2013 as the Director of the Department of Oncology and Cancer Center at the University Hospital in Zurich, Switzerland. He moved in 2017 to take up his current positions at Northwestern University in Chicago. He has been a member of the European Organization for Research and Treatment of Cancer (EORTC) since 1994, and serves as the President of the organization since 2012. Dr. Stupp’s research focuses on early drug development, the combination of chemo- and radiotherapy, multidisciplinary cancer management, namely in the areas of lung cancer and brain tumors. He is involved in bringing innovative and multimodal treatments to the clinic. Roger Stupp has been the principal investigator for large multimodality clinical trials in brain tumors and non-small cell lung cancer.

Dr. Stupp is section editor for the European Journal of Cancer. He serves in scientific or educational committees of the European Society of Medical Oncology (ESMO) and the American Society of Clinical Oncology (ASCO); he also acts as a consultant for several European and National funding agencies.

Enriqueta Felip

Head of the Thoracic Cancer and the Head and Neck Cancer Units within the Oncology Department of Vall d’Hebron University Hospital, Barcelona, Spain

Enriqueta Felip is Head of the Thoracic Cancer and the Head and Neck Cancer Units within the Oncology Department of Vall d’Hebron University Hospital, Barcelona, Spain. She is also Associate Professor at the Autonomous University of Barcelona (UAB). Enriqueta Felip received her medical degree from the UAB, where she also completed her PhD studies in medical oncology.

Professor Felip is in charge of thoracic malignancy management, and is responsible for thoracic cancer trials undertaken by the Oncology Department. Current research lines include the individualization of chemotherapy in early-stage disease, the use of pharmacogenomic approaches, the evaluation of new drugs, and the optimization of immunotherapy strategies.

She is currently a member of the Spanish Lung Cancer Group (SLCG), the Spanish Society of Medical Oncology (SEOM), the European Society of Medical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), the International Association for the Study of Lung Cancer (IASLC) and the National Lung Cancer Partnership. She is the coordinator of the lung cancer program of the European School of Oncology (ESO). Dr Felip is also author of many peer-reviewed articles and book chapters relating to the field of thoracic malignancies.

CEO Laura Soucek presented with European Award for Female Entrepreneurs by the Asociación Europea de Economía y Competitividad

At a special dinner on 15thMarch 2019, Dr Soucek was given the award by the Asociación Europea de Economía y Competitividad (AEDEEC) with the goal of celebrating the excellence, competitivity and influence of women and to demonstrate their support of women in business. This is the first edition of the European Awards to Female Entrepreneurs. The ceremony took place in the Hotel Suites Mira Sierra, and was presented by the journalist Emilio Javier Gómez Plaza, an honorary member of AEDEEC, who commented on behalf of the Association that it was “totally necessary to pay a small tribute to women who have succeeded in leading teams and launching all manner of successful project***

Laura commented that it was “an honour to receive such an award, and a particularly special evening meeting so many remarkable and smart women who have been successful in a diverse range of businesses”.

At Peptomyc we believe in forging strategic partnerships that will ultimately enable us to drive Myc inhibition into the clinic as an effective anti-cancer therapy across multiple tumor types. We therefore welcome your interest, questions or any queries you may have surrounding Peptomyc. Please do contact us direct***

Chief-Executive-Officer：Laura Soucek

Email：lsoucek**[ta]**omyc.com

Chief-Scientific-Officer：Marie-Eve Beaulieu

Email：mbeaulieu**[ta]**omyc.com

Peptomyc’s business model consists of de-risking Omomyc-CPP from a Proof of Concept Development Stage into a successful Phase I/II product and then Licensing it to a Pharmaceutical company.

Peptomyc is currently looking for investors in order to fund the clinical development of Omomyc. Should you have any enquiries please contact lsoucek**[ta]**omyc.com.